In training cohort, we carried out the association between the FRlncRNAs signature and six common ICB therapy-related targets (PD-1, PD-L1, PD-L2, TIM-3, IDO1, and CTLA-4) to explore the potential role of FRlncRNAs signature in the immunotherapy of ICB in the patients with HCC. Here, RPL17 is linked to hepatocellular carcinoma.